FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B Turnover 20.45%
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+24.25%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.59B
AUM Growth
+$706M
Cap. Flow
-$31.5M
Cap. Flow %
-0.69%
Top 10 Hldgs %
73.61%
Holding
44
New
6
Increased
8
Reduced
2
Closed
3
Avg Time Held
1.8 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.8 years

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$53.1M
2
ALLO icon
Allogene Therapeutics
ALLO
+$41M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$37.7M
4
ACHV icon
Achieve Life Sciences
ACHV
+$36.3M
5
KLRA icon
Kailera Therapeutics
KLRA
+$24.2M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$133M
2
KALV icon
KalVista Pharmaceuticals
KALV
+$99.9M
3
RVMD icon
Revolution Medicines
RVMD
+$65.7M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$42.5M
5
TRVI icon
Trevi Therapeutics
TRVI
+$1.45K

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Miscellaneous 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MIRM icon
1
Mirum Pharmaceuticals
MIRM
$5.19B
$899M 19.58%
7,679,684
– –
2022 Q1
17 quarters
NAMS icon
2
NewAmsterdam Pharma
NAMS
$2.39B
$613M 13.35%
18,088,902
+1,145,128
+7% +$37.7M
2022 Q4
14 quarters
ERAS icon
3
Erasca
ERAS
$5.14B
$458M 9.96%
24,975,188
+300,000
+1% +$4.29M
2024 Q2
8 quarters
MBX icon
4
MBX Biosciences
MBX
$2.35B
$367M 8%
6,652,013
– –
2024 Q3
7 quarters
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.32B
$259M 5.64%
9,874,511
– –
2022 Q1
17 quarters
TRVI icon
6
Trevi Therapeutics
TRVI
$1.72B
$185M 4.04%
9,939,447
-100
-0% -$1.45K
2022 Q2
16 quarters
KRYS icon
7
Krystal Biotech
KRYS
$9.79B
$179M 3.9%
481,307
– –
2022 Q1
17 quarters
MAZE icon
8
Maze Therapeutics
MAZE
$1.46B
$150M 3.27%
5,032,915
+465,641
+10% +$12.2M
2025 Q1
5 quarters
PHAT icon
9
Phathom Pharmaceuticals
PHAT
$599M
$135M 2.95%
12,466,489
– –
2022 Q1
17 quarters
PVLA icon
10
Palvella Therapeutics
PVLA
$1.77B
$135M 2.94%
882,400
– –
2024 Q3
7 quarters
BBIO icon
11
BridgeBio Pharma
BBIO
$12.7B
$115M 2.51%
1,548,139
-1,900,000
-55% -$133M
2023 Q1
13 quarters
IRON icon
12
Disc Medicine
IRON
$2.14B
$99.1M 2.16%
1,354,852
– –
2023 Q2
12 quarters
CYTK icon
13
Cytokinetics
CYTK
$8.82B
$98.8M 2.15%
1,159,879
– –
2025 Q2
4 quarters
DYN icon
14
Dyne Therapeutics
DYN
$2.81B
$70M 1.53%
3,153,082
– –
2025 Q1
5 quarters
ASND icon
15
Ascendis Pharma A/S
ASND
$14.9B
$60.1M 1.31%
225,155
+91,822
+69% +$21.4M
2024 Q3
7 quarters
SVRA icon
16
Savara
SVRA
$978M
$59.9M 1.3%
9,720,852
– –
2023 Q3
11 quarters
PBLS
17
Parabilis Medicines Inc
PBLS
$3.2B
$52.6M 1.14%
+1,920,805
New +$53.1M
2026 Q2
0 quarters
AURA icon
18
Aura Biosciences
AURA
$640M
$50.4M 1.1%
7,100,000
+2,000,000
+39% +$14.3M
2025 Q2
4 quarters
ACHV icon
19
Achieve Life Sciences
ACHV
$722M
$49.7M 1.08%
+7,614,836
New +$36.3M
2026 Q2
0 quarters
VOR icon
20
Vor Biopharma
VOR
$1.11B
$46.8M 1.02%
2,543,939
– –
2025 Q4
2 quarters
ALLO icon
21
Allogene Therapeutics
ALLO
$449M
$46.7M 1.02%
22,446,668
+18,650,000
+491% +$41M
2024 Q1
9 quarters
TARS icon
22
Tarsus Pharmaceuticals
TARS
$3.38B
$45.9M 1%
728,644
– –
2022 Q1
17 quarters
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.06B
$40.1M 0.87%
4,009,240
– –
2026 Q1
1 quarter
ALKS icon
24
Alkermes
ALKS
$6.56B
$36.7M 0.8%
700,647
– –
2024 Q3
7 quarters
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$3.32B
$36.4M 0.79%
1,438,198
– –
2025 Q3
3 quarters
1
2

Similar funds

BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
MR
Munich Reinsurance Munich $4.57B AUM 28.39% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2026 Portfolio in Review

As of Q2 2026, Frazier Life Sciences Management held 44 positions worth $4.59B, up 18% from $3.89B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Frazier Life Sciences Management's Q2 2026 filing shows 6 new, 8 increased, 2 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M. The largest sale was BridgeBio Pharma, an estimated $133M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • Frazier Life Sciences Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M.
  • Frazier Life Sciences Management added most to Allogene Therapeutics in Q2 2026, an estimated $41M increase.
  • Frazier Life Sciences Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $133M.
  • Frazier Life Sciences Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $99.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 74% of its $4.59B portfolio in Q2 2026.
  • Frazier Life Sciences Management opened 6 new positions and closed 3 in Q2 2026.
  • Frazier Life Sciences Management's portfolio value rose 18% quarter-over-quarter to $4.59B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.